Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$0.41 - $0.91 $2,456 - $5,451
-5,991 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$11.06 - $14.01 $7,852 - $9,947
710 Added 13.44%
5,991 $66,000
Q3 2020

Nov 13, 2020

SELL
$10.26 - $14.55 $12,547 - $17,794
-1,223 Reduced 18.8%
5,281 $64,000
Q2 2020

Aug 05, 2020

BUY
$7.11 - $13.76 $5,872 - $11,365
826 Added 14.55%
6,504 $89,000
Q3 2019

Nov 14, 2019

BUY
$12.16 - $21.0 $7,198 - $12,432
592 Added 11.64%
5,678 $69,000
Q2 2019

Aug 14, 2019

BUY
$9.44 - $19.8 $14,707 - $30,848
1,558 Added 44.16%
5,086 $101,000
Q2 2018

Aug 13, 2018

BUY
$15.88 - $19.5 $46,591 - $57,213
2,934 Added 493.94%
3,528 $66,000
Q4 2017

Feb 14, 2018

BUY
$14.41 - $19.15 $8,559 - $11,375
594
594 $9,000

Others Institutions Holding ATNX

About Athenex, Inc.


  • Ticker ATNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 156,790,000
  • Market Cap $1.57M
  • Description
  • Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...
More about ATNX
Track This Portfolio

Track Ameritas Investment Partners, Inc. Portfolio

Follow Ameritas Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.